Randomized Trial: JAK1 Inhibitor vs. Placebo for the Treatment of Refractory Moderate to Severe Rheumatoid Arthritis
24 Jul, 2019 | 01:23h | UTCEffect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis (free for a limited period)